Skip to main content
Norris Cotton Cancer Center
In This Section

A Phase I Trial of BNC105P and Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Principal Investigator

Lionel Lewis

Study Number



A Phase I Trial of BNC105P in combination with BTK inhibitor ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia(CLL). This study proposes that ibrutinib will have far greater efficacy when it is combined with drugs that kill the CLL cells in peripheral circulation, thereby preventing them from returning to the protective lymph node niche. The study will establish the maximum tolerated dose(MTD) of the combination of BNC105P with ibrutinib, characterize the pharmacodynamic effects of BNC105P alone and in combination with ibrutinib in CLL cells, and provide preliminary assessment of the efficacy of the combination in CLL. The study consists of a Screening Period with baseline tumor assessment before BNC105P administration, a Treatment Period with up to six 21-day cycles and Follow-up Period. Subjects will receive a total of six cycles of therapy unless treatment is discontinued


Phase I


Bridget Labrie

Available at the following location(s)

  • Lebanon

View more details at

Do you need help with some of the labels on this page?
Read our glossary of terms